SCHEMBL972907

SCHEMBL972907

Cc1nc(C2CCCCC2)n2c1c(=O)[nH]c1ccc(Cl)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
PDE9A O76083 3/20 0.41
PDE10A Q9Y233 2/20 0.40
PDE5A O76074 2/20 0.40
PDE1A P54750 2/20 0.40
PDE1B Q01064 2/20 0.40
PDE1C Q14123 2/20 0.40
PDE2A O00408 2/20 0.40
PDE6D O43924 1/20 0.40
PDE8A O60658 1/20 0.40
PDE8B O95263 1/20 0.40
PDE6A P16499 1/20 0.40
PDE6G P18545 1/20 0.40
PDE4A P27815 1/20 0.40
PDE6B P35913 1/20 0.40
PDE6C P51160 1/20 0.40
PDE4B Q07343 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL970128 0.87 OPRM1 (0.46) KMT2AMEN1POLBPDE9APDE10A
SCHEMBL3591359 0.84 L3MBTL1 (0.43) KMT2AMEN1POLBPDE9APDE10A
SCHEMBL16628604 0.81 PDE9A (0.40) KMT2AMEN1POLBPDE9APDE10A
SCHEMBL3595821 0.80 ALDH1A1 (0.43) KMT2AMEN1POLBPDE9APDE10A
SCHEMBL968420 0.79 PDE10A (0.55) PDE10APDE2A
SCHEMBL971045 0.77 PDE10A (0.47) KMT2AMEN1PDE10APDE2A
SCHEMBL11997315 0.76 ALDH1A1 (0.42) KMT2APDE9APDE7A
SCHEMBL3595214 0.75 TLR8 (0.42) KMT2AMEN1POLBPDE9APDE10A
SCHEMBL972909 0.74 ADORA3 (0.53) CSF1RKMT2AMEN1POLBPDE9A
SCHEMBL3598763 0.74 PDE9A (0.57) KMT2AMEN1POLBPDE9APDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875618-B2 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) WYETH (US) 2011-01-25 US disclosed
EP-2225248-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 Wyeth LLC (US) 2010-09-08 EP disclosed
WO-2009070584-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 WYETH (US) 2009-06-04 WO disclosed
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 ELBION GMBH (DE) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 PDE12, PDE5A, PDE10A CSF1R 3579/4885KMT2A 2253/4885MEN1 2827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.